183 related articles for article (PubMed ID: 18467090)
1. Predictive markers of response to neoadjuvant chemotherapy in breast cancer.
Tewari M; Krishnamurthy A; Shukla HS
Surg Oncol; 2008 Dec; 17(4):301-11. PubMed ID: 18467090
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
Faneyte IF; Schrama JG; Peterse JL; Remijnse PL; Rodenhuis S; van de Vijver MJ
Br J Cancer; 2003 Feb; 88(3):406-12. PubMed ID: 12569384
[TBL] [Abstract][Full Text] [Related]
5. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
Colleoni M; Viale G; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S137-40. PubMed ID: 19914533
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.
Mathew J; Asgeirsson KS; Cheung KL; Chan S; Dahda A; Robertson JF
Eur J Surg Oncol; 2009 Feb; 35(2):113-22. PubMed ID: 18502088
[TBL] [Abstract][Full Text] [Related]
7. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
Kim R; Osaki A; Toge T
Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemotherapy treatment of breast cancer--a review.
Buzdar AU
Cancer; 2007 Dec; 110(11):2394-407. PubMed ID: 17941030
[TBL] [Abstract][Full Text] [Related]
9. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
Nagasaki K; Miki Y
Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
11. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
Jeruss JS; Mittendorf EA; Tucker SL; Gonzalez-Angulo AM; Buchholz TA; Sahin AA; Cormier JN; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2008 Jan; 26(2):246-52. PubMed ID: 18056680
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
[TBL] [Abstract][Full Text] [Related]
13. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
14. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer: role of neoadjuvant therapy.
Ahmed MI; Lennard TW
Int J Surg; 2009 Oct; 7(5):416-20. PubMed ID: 19524705
[TBL] [Abstract][Full Text] [Related]
16. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
van Nes JG; Putter H; Julien JP; Tubiana-Hulin M; van de Vijver M; Bogaerts J; de Vos M; van de Velde CJ;
Breast Cancer Res Treat; 2009 May; 115(1):101-13. PubMed ID: 18484198
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant treatment of breast cancer: implications for the pathologist].
Le Guellec S; Perallon R; Alunni JP; Charitansky H; Leaha C; Gonzalez AM; Chateau MC; Simony-Lafontaine J; Jacot W; Gutowski M; Penault-Llorca F; Dalenc F; Lacroix-Triki M
Ann Pathol; 2011 Dec; 31(6):442-54. PubMed ID: 22172117
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
19. The role of primary chemotherapy in early breast cancer.
Harris L; Swain SM
Semin Oncol; 1996 Feb; 23(1 Suppl 2):31-42. PubMed ID: 8614843
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
